AAP
ANRO icon

Arax Advisory Partners’s Alto Neuroscience ANRO Stock Holding History

Arax Advisory Partners’s Portfolio ANRO Stock Details ANRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$112 Hold
5
– – ﹤0.01% 3602
2025
Q4 		$89 Sell
5
-37
-88% -$466 ﹤0.01% 3848
2025
Q3 		$169 Buy
+42
New +$139 ﹤0.01% 3461

Other funds holding ANRO

AWG
Alpha Wave Global New York $791M AUM 113.77% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
SSC
Spruce Street Capital New York $416M AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Arax Advisory Partners's ANRO Position: Q1 2026 in Review

Arax Advisory Partners held its Alto Neuroscience (ANRO) position steady in Q1 2026 at 5 shares worth $112. The position accounts for ﹤0.01% of the portfolio, ranked #3602.

Arax Advisory Partners first reported a position in ANRO in Q3 2025 and has held it in 3 quarters since. The position peaked at $169 in Q3 2025. 110 funds tracked by Wall St. Rank hold ANRO as of Q1 2026.

  • Arax Advisory Partners held 5 shares of Alto Neuroscience worth $112 as of Q1 2026.
  • Arax Advisory Partners left its Alto Neuroscience share count unchanged in Q1 2026.
  • Alto Neuroscience made up ﹤0.01% of Arax Advisory Partners's portfolio in Q1 2026, its #3602 holding.
  • Arax Advisory Partners first reported a position in Alto Neuroscience in Q3 2025 and has held it in 3 quarters since.
  • Arax Advisory Partners's Alto Neuroscience position peaked at $169 in Q3 2025.
  • 110 funds tracked by Wall St. Rank held Alto Neuroscience as of Q1 2026.

Based on Arax Advisory Partners's 13F filing for Q1 2026, filed 13 May 2026.